Intraday Info: Dipexium Pharmaceuticals Inc (NASDAQ:DPRX) locked on 20/12/2016 at $1.65. It has average volume $328,771 whilst it totals volume 210,283. The company has EPS -2.07 and according to analysts next quarter EPS and next year estimate EPS will -0.35 and -1.57 respectively. And it total income 21.40 million.
Ownership Summary: Dipexium Pharmaceuticals Inc has total institutional ownership 26.55% while its total outstanding shares 10 millions that’s value of holdings $4 million.
Active Positions: In the latest year, DPRX 23 holders have raised its positions while it contains total 301,893 shares. And the strength of reduced positions holders and held positions holders are 14 and 3 respectively.
New and Sold Out Positions: In DPRX force of new positions holders 6 and it has total shares 39,974. And force of sold out positions holders 7 and it has 114,686 shares.
Comparison with Other Company: The Market Value of DPRX is $16,642 below from AbbVie Inc. market value which is $99M. Current Last Sale of DPRX is $1.6 below from ABBV current last sale which is $61.45.
Dipexium Pharmaceuticals Inc said economic consequences for the region ended September 30, 2016.
For the three months ended September 30, 2016, Dipexium said a net lack of $four.6 million, comparison to a net lack of $5.0 million for the 3 months ended September 30, 2015, a lower of $0.4 million. The trade become specifically because of a $zero.5 million lower in production concerning expenses offset by using a $zero.1 million increase in segment three medical trial associated costs.
For the 9 months ended September 30, 2016, Dipexium stated a internet lack of $15.9 million, contrast to a net lack of $13.2 million for the 9 months ended September 30, 2015, a lift of $2.7 million. this variation changed into especially because of a $2.nine million growth in studies and improvement fees in part offset by way of a $0.2 million lower in selling, general, and administrative charges. The increase in research and development charges have been because of $2.9 million of raised section three trial enrollment and related clinical trial expenses. The lower in popular and administrative costs is mainly attributable to a lower of $0.1 million for stock-based totally repayment charges and a $0.1 million lower in advertising related expenses.
Internet cash utilized in operating sports for the nine months ended September 30, 2016 was $13.4 million as assessment to $10.6 million for the nine months ended September 30, 2015. The boom in coins utilized in operating activities is mainly attributable to raised studies and improvement costs related to raised segment 3 trial enrollment and related clinical trial expenses.